top of page

IB COMMUNICATIONS PRESS RELEASES

2024

BioSenic

31 January 2024

BioSenic provides support to forthcoming European conference on graft-versus-host disease.

Mont-Saint-Guibert, Belgium, January 31, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD).

CellQuest

16 January 2024

CellQuest launches Early Access Program with first CosyNest automated CAR-T manufacturing partner

Besançon, France, January 16, 2024 – CellQuest, a developer and manufacturer of automated chimeric antigen receptor (CAR)-T cell production platforms and solutions, today announces the launch of its Early Access Program (EAP) to introduce the CosyNest manufacturing platform to cell therapy developers. CosyNest, a closed manufacturing system, has been designed to dramatically increase the production of CAR-T cells per person, and per unit area.

OrganaBio

16 January 2024

OrganaBio Named Translation Award Finalist for Supporting CAR-NKT Cell Therapies into Clinical Trials

Miami, Florida, January 16, 2024 – OrganaBio, the hub for tissue sourcing, cell isolation, clinical sample processing, cryopreservation, and contract manufacturing services to support cell therapy and immunotherapy development globally, has been named a Translator of the Year finalist at the upcoming Advanced Therapies Awards for its work to support a chimeric antigen receptor natural killer T-cell (CAR-NKT) therapy as it progresses into clinical trials.........

BioSenic

15 January 2024

BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment

Mont-Saint-Guibert, Belgium, January 15, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of a binding term sheet with Phebra PTY Ltd. related to the adaptation of the License Agreement and the MDA signed in May 2021.

BioSenic

10 January 2024

BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer

Mont-Saint-Guibert, Belgium, January 10, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO).

BioSenic

8 January 2024

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

Mont-Saint-Guibert, Belgium, January 8, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the company addressing unmet medical needs in auto-immune diseases and orthopedics, today announces that it has signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15").

bottom of page